CureMatch to Exhibit and Share Advances in Precision Medicine at PMWC 2018
CureMatch® to exhibit and share advances in precision medicine at The Precision Medicine World Conference, PMWC 2018; to highlight the CureMatch PreciGENE™ report which is used to guide oncologists in the selection of a personalized cancer treatment plan, using supercomputing and the latest discoveries in genomics and proteomics.
SAN DIEGO, CA – January 18, 2018 – CureMatch® presents the latest advances with the PreciGENE™ report at the Precision Medicine World Conference (PMWC) January 22-24, Silicon Valley. Stop by and visit CureMatch at booth #4 near the main stage.
Stephane Richard, CEO of CureMatch says, “There’s so much more work to be done and we are excited to be at the forefront of matching potential cures. We now provide a suggested ranked and scored list of combination treatment options which would have taken days if not weeks for one oncologist to research. We’re finding this is not only a time saver but a potential lifesaver for some – and our databases are growing each day.”
CureMatch’s PreciGENE reporting has even further potential. Oncologists and pharmaceutical companies today can use this system to input specific drug choices to score and rank them among millions of possible treatment options for an individual patient. This breakthrough technology will enable clinician decision makers to understand how well a proposed cancer treatment option is expected to match a patient’s biomarker profile relative to the latest advances in precision oncology.
About PMWC 2018
The Precision Medicine World Conference (PMWC), is in its 13th installment and 2018’s event in Silicon Valley will traverse innovative technologies, thriving initiatives, and clinical case studies to enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand from companies such as CureMatch about the latest developments and advancements in precision medicine and the cutting-edge new strategies and solutions changing how patients are treated today.
CureMatch®, Inc. is a San Diego-based digital precision oncology company focused on personalized medicine and combination therapy. CureMatch Reports guide oncologists with actionable intelligence to customize treatment for each individual patient based on each specific molecular tumor profile. Precision medicine is considered by many to be the future of cancer treatment as combination therapy has been used effectively in the treatment of other diseases, such as HIV/AIDS. The CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com
Name: Larissa Anderson